Recent Updates
Recently added Catalysts
PEPG Negative Sentiment Score: 25/100

PEPGEN (PEPG) FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds PepGen Investors of the August 8th Deadline and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against PepGen, Inc. for allegedly making false and misleading statements about the company's business and clinical trials. The lawsuit covers securities purchased between March 7, 2024 and March 3, 2025, with a deadline for investors to apply as lead plaintiff by August 8, 2025. Key allegations include concerns over the drug PGN-EDO51's effectiveness and the safety of the CONNECT2 study, which could jeopardize the company's prospects. Investors are encouraged to contact the law firm for more details on their rights.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against PepGen due to misleading statements.
  • Concerns over the effectiveness and safety of PGN-EDO51.
  • Allegations that the CONNECT2 study may halt, impacting drug prospects.
  • Investors have suffered losses due to these public misrepresentations.

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In PepGen (PEPG) To Contact Them Directly To Discuss Their Options
If you purchased or acquired securities in PepGen between March 7, 2024 and March 3, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
NEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against PepGen, Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). Investors have until August 8, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) PGN-EDO51 was less effective and safe than Defendants had led investors to believe; (ii) the CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired PepGen shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Tags

Bragar Eagel & Squire

Frequently Asked Questions

Who can participate in the PepGen class action lawsuit?

Individuals or entities who acquired PepGen securities between March 7, 2024, and March 3, 2025, can participate.

What are the allegations against PepGen in the lawsuit?

The lawsuit alleges false and misleading statements regarding PGN-EDO51's effectiveness and safety.

How can I contact Bragar Eagel & Squire regarding PepGen?

You can contact them by calling (212) 355-4648 or emailing investigations@bespc.com.

What is the deadline to apply as lead plaintiff in the lawsuit?

The deadline to apply as lead plaintiff is August 8, 2025.

Is there a cost to discuss my legal options with Bragar Eagel & Squire?

There is no cost or obligation to discuss your legal options with the firm.

Last updated: Aug 7, 2025